<DOC>
	<DOCNO>NCT00641017</DOCNO>
	<brief_summary>Human Parainfluenza Virus Type 1 ( HPIV1 ) lead cause viral respiratory infection child , elderly , compromise immune system . HPIV1 also lead cause viral croup child 6 year old . The purpose study determine safety immune response HPIV1 vaccine , rHPIVI1 84/del170/942A , 2 group adults child previously expose HPIV1 . Once safety vaccine establish group , additional 2 group infant child previously expose HPIV1 vaccinate . Na√Øve infants child vulnerable naturally circulate HPIV1 target population vaccine .</brief_summary>
	<brief_title>Safety Immune Response Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine</brief_title>
	<detailed_description>HPIV1 infection result severe respiratory illness often lead hospitalization infant young child . HPIV1 responsible approximately 6 % pediatric hospitalization respiratory tract disease main cause severe low respiratory tract disease , include pneumonia bronchiolitis child less 6 year old . The purpose study determine safety immune response HPIV1 vaccine , rHPIVI1 84/del170/942A , 5 main volunteer group : first adult ( group 1 2 ) , seropositive child ( group 3 ) . The last 2 group seronegative infant child split 2 dose group ; one group seronegative infant child receive low dose vaccine ( group 4 ) second group seronegative infant child ( group 5 ) receive high dose vaccine . This study last approximately 8 week per group . Additional information group follow : Groups 1 2 consist 35 adult total , 18 49 year age . These group receive one immunization rHPIV1 84/del170/942A study entry . Immunization give nose drop . Study visit occur Days 3 , 4 , 5 , 6 , 7 , 10 , 28 . Medical history , vital sign , clinical assessment , nasal wash occur visit . Blood urine test occur select visit . A urine pregnancy test occur female study entry . Follow-up phone report also require Day 56 . Enrollment Group 3 begin safety data Groups 1 2 evaluate . Group 3 consist 15 seropositive child , 15 59 month age . This group receive either one immunization rHPIV1 84/del170/942A placebo study entry . Immunization give nose drop . Study visit occur Days 3 , 4 , 5 , 6 , 7 , 10 , 28 . Medical history , vital sign , clinical assessment , nasal wash occur visit . Blood urine test occur select visit . Parents required submit report phone throughout study . These report include temporal temperature previous day . Enrollment Group 4 begin safety data Group 3 evaluate . Group 4 consist 21-30 seronegative infant child , 6 59 month age . This group receive either one immunization rHPIV1 84/del170/942A placebo study entry . Immunization give nose drop . Study visit occur Days 3 , 5 , 7 , 10 , 12 , 14 , 17 , 19 , 21 , 28 , 56 . Medical history , vital sign , clinical assessment , nasal wash occur visit . Blood test occur select visit . Parents required submit report phone throughout study . These report include temporal temperature previous day . Enrollment Group 5 begin safety data Group 4 evaluate . Group 5 consist 21-30 seronegative infant child 6 59 month age . This group receive either one immunization rHPIV1 84/del170/942A placebo study entry . The immunization give nose drop . The vaccine dosage participant receive Group 5 great dose Group 4 . Study visit occur Days 3 , 5 , 7 , 10 , 12 , 14 , 17 , 19 , 21 , 28 , 56 . Medical history , vital sign , clinical assessment , nasal wash occur visit . Blood test occur select visit . Parents required submit report phone throughout study . These report include temporal temperature previous day .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult In good health Available duration trial Available postinoculation telephone contact For female , must agree use effective birth control method duration study Seropositive Children In good health Seropositive HPIV1 Available duration study Seronegative Infants Children In good health Seronegative HPIV1 antibody Available duration study Adult Neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Condition , opinion investigator , allow participant comply protocol Alcohol drug abuse History anaphylaxis History splenectomy Diagnosis asthma within 2 year study entry HIVinfected Hepatitis C infection Hepatitis B infection Abnormal urinalysis Known immunodeficiency syndrome Current use nasal systemic steroid medication Receipt blood product within 3 month study entry Current smoker unwilling stop smoking duration study . The decision exclude potential subject make investigator base upon potential subject 's medical history physical examination . Participation another investigational vaccine drug trial within 30 day receive investigational vaccine Receipt live vaccine within 4 week kill vaccine within 2 week immune globin within 3 month prior receive investigational vaccine Previous immunization HPIV1 vaccine Known hypersensitivity vaccine component Participants whose profession and/or personal responsibility involve care child less 6 month age immunosuppressed individual Persistent systolic blood pressure 140 mm Hg diastolic pressure 90 mm Hg Body mass index ( BMI ) 35 Pregnant breastfeed Seropositive Seronegative Infants Children Known suspect impairment immunological function determine investigator Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previous immunization HPIV1 vaccine Current use nasal systemic steroid medication Previous serious vaccineassociated adverse event anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include reactive airway disease determine investigator Member household include immunocompromised individual infant le 6 month age Attends day care infant less 6 month age immunosuppressed individual . More information criterion find protocol . Participation another investigational vaccine drug trial within 30 day receive investigational vaccine study occur</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>